Mumbai-based Ipca Laboratories and Bhami's Research Laboratory (BRL) have entered into a definitive global licensing agreement that grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform. According to reports from CNBC TV18, the collaboration was announced on June 12, 2026, and will focus on the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases. The licensing arrangement covers worldwide rights, with BRL receiving a defined milestone fee related to the technology transfer and royalties on net sales upon commercialisation of the products. Under the agreement, BRL is responsible for proof of concept and formulation development, while Ipca will handle further research and development, clinical trials, commercial manufacturing, and product launch. As per BRL Co-founder and CEO Dr Suryakanth M Pai, the partnership is designed to make patient care convenient, affordable, and safe by expanding the reach of the company's proprietary and patented subcutaneous protein delivery platform technology.
Commenting on the partnership, Pranay Godha, Managing Director and Chief Executive Officer of Ipca Laboratories, stated that the collaboration combines Ipca's scientific capabilities with BRL's formulation platform to accelerate the development of affordable biologics for patients battling cancer and autoimmune diseases globally. According to CNBC TV18, Dr Suryakanth M Pai, BRL Co-founder and Chief Executive Officer, emphasized that the partnership is designed to make patient care convenient, affordable, and safe by expanding the reach of the company's proprietary and patented subcutaneous protein delivery platform technology. The collaboration leverages BRL's novel formulation technology alongside Ipca's established scientific capabilities to accelerate the creation of affordable biologics for global markets.
Ipca Laboratories, established in 1949, is a vertically integrated pharmaceutical company with a strong presence in over 120 countries. It has made significant strides in developing in-house capabilities in biosimilars and biologicals, with a world-class bio-manufacturing facility and R&D center. Bhami Research Laboratory (BRL), founded 12 years ago, is headquartered in Mangalore, India. BRL is dedicated to reimagining patient-friendly, affordable biologics drug delivery, with core expertise in protein and peptide drug delivery. BRL is focused on patient-friendly delivery of biologic therapeutics through its proprietary high-concentration subcutaneous protein delivery and oral biologics delivery platform technologies. WeTranslate served as BRL's strategic licensing partner, facilitating the development and execution of this collaboration.
Akhil Shah, Director and Chief Executive Officer of WeTranslate, highlighted that BRL has built a differentiated formulation technology platform, while Ipca brings the scale, expertise and global reach required for commercialisation. According to CNBC TV18, WeTranslate expressed pleasure in supporting the collaboration and its potential impact on biologic drug delivery. The partnership combines BRL's innovative technology with Ipca's established market presence and distribution capabilities. This new subcutaneous formulation development is expected to enhance Ipca's product portfolio across key markets including the USA, UK, EU, Japan, Canada, and India. The collaboration aims to develop and commercialize multiple monoclonal antibody products targeting oncology and inflammatory diseases, enhancing Ipca's biosimilar portfolio and global market reach.
Ipca Laboratories reported steady fourth-quarter earnings with growth in domestic formulations and exports helping improve revenue and operating margins during the March quarter. As reported by CNBC TV18, profit before exceptional items and tax rose to ₹450 crore in Q4FY26 from ₹333 crore a year ago. Revenue for the quarter increased 6.3% year-on-year to ₹2,388.5 crore, while EBITDA rose 12.7% to ₹484 crore. Shares of Ipca Laboratories Ltd ended Friday's session at ₹1,589 apiece on the NSE, down 1.52% or ₹24.60 from the previous close.
